VolitionRx shares surge 10.79% premarket as company prepares Nu.Q® Cancer assay reimbursement submission in France with HCL support.

Volitionrx surged 10.79% in premarket trading following the announcement that it prepared a reimbursement submission for its Nu.Q® Cancer assays in France, supported by the country’s second-largest hospital system, Hospices Civils de Lyon (HCL). The submission under the RIHN framework aims to secure coverage for the test, enabling its routine clinical use in lung cancer management, with potential implementation by late 2026. The company emphasized that reimbursement represents a pivotal commercialization milestone, with France’s 50,000 annual lung cancer diagnoses offering significant market potential. HCL’s endorsement and the test’s demonstrated clinical utility in identifying curative treatment candidates further underscore the strategic importance of this development.